The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
we do know that there's one other really important readout we're waiting for which is um Matt cabin's dog aging study um which uh is is is going to be an exciting readout in 2026 um we're also waiting for another readout out of the University of San Antonio looking at another um another trial in mammals
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
so there are research studies in the context of Aging in marmosets they're very small and and very early but but those are being done at the University of Texas or San Antonio yeah Texas San Antonio the Barshop Institute and then there are a variety of cancer studies in dogs with rapamycin so there's a large study of rapamycin for osteosarcoma in dogs and then there are a few smaller clinical trials
I have a relatively strong conviction it's modestly held um it will be a lot more of a strong conviction one way or the other and I'll tighten my grip on it in 2026 which is about the time when when we'll have the read out of this study
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.